2cureX AB (publ) (STO:2CUREX)

Market Cap	56.15M +11.8%
Revenue (ttm)	1.98M -49.7%
Net Income	-26.35M
EPS	-1.50
Shares Out	31.90M
PE Ratio	n/a
Forward PE	n/a
Dividend	0.08 (4.77%)
Ex-Dividend Date	Jun 27, 2025

Volume	5,561
Open	1.758
Previous Close	1.760
Day's Range	1.700 - 1.758
52-Week Range	0.514 - 5.480
Beta	3.06
Analysts	n/a
Price Target	n/a
Earnings Date	May 21, 2026

About 2cureX AB

2cureX AB (publ) operates as a medical technology company in Europe. Its proprietary IndiTreat test family creates various 3D tumor replicas—called tumoroids—from a patient’s biopsy to identify which chemotherapy or targeted drugs that are effective for that specific tumor. 2cureX AB (publ) was incorporated in 2006 and is based in Landskrona, Sweden.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 14
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: 2CUREX

Financial Performance

In 2023, 2cureX AB's revenue was 2.95 million, a decrease of -12.53% compared to the previous year's 3.37 million. Losses were -32.52 million, 9.23% more than in 2022.